Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Signal Transduction

 

Group Leader
Professor Roger Daly

 

The Signal Transduction Group studies mechanisms of hormone and growth factor signalling and how these are altered in disease states, particularly cancer. Our current research focuses on three proteins involved in either the transmission of signals within the cell or the regulation of these signalling events: Gab2, cortactin and Grb14. Overexpression of Gab2, which is found in a subset of breast cancers, increases not only the proliferation of cancer cells but also their invasive properties. The latter effect suggests that Gab2 may promote cancer cell spread throughout the body. High levels of cortactin are found in some breast and head and neck cancers, and we have identified that this protein increases resistance to a new drug currently in clinical development. Together with researchers in the Diabetes Program, we are studying how Grb14, and related proteins, regulate the metabolic and growth-promoting effects of insulin and insulin-like growth factors.

Staff

b_browne90.jpgResearch Officer
Dr Brigid Browne
Naveid AliResearch Officer
Dr Naveid Ali
Ruth LyonsSenior Research Assistant
Ruth Lyons
Ling LiuResearch Officer
Dr Ling Liu
Howard ChanResearch Assistant
Howard Chan
Brian LeePhD Student
Brian Lee
Emily StoddartPhD Student
Emily Stoddart
Carole TactacanPhD Student
Carole Tactacan


Luxi ZhangPhD Student
Luxi Zhang



 

 

 

News

 

Taking the fingerprint of basal breast cancer

MEDIA RELEASE: 29 Sep 2010
Australian researchers have used sophisticated new protein screening technology to profile basal breast cancer, a particularly aggressive sub-type of breast cancer, identifying specific targets for future treatments.
 
 

Falko Hochgräfe wins proteomics award

29 Sep 2010
Dr Falko Hochgräfe, postdoctoral researcher at Garvan, was awarded the Human Proteome Organisation (HUPO) Young Guns Early Career Research Award last week. Fifteen of the field’s brightest young researchers were shortlisted from around the world to present their findings at HUPO’s 9th Annual World Congress held in Sydney.
 
 

First step towards switching off breast cancer and leukaemia

MEDIA RELEASE: 08 Aug 2008
Garvan scientists have identified a way to ‘switch off’ a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia. The molecule, known as Gab2, operates downstream of a major breast cancer oncogene, HER2, the target of the drug Herceptin.
 
 

Personal tools